Br J Cancer: Serum A fetal protein levels and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Remo reed monotherapy

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide.
in the prognosis of liver cancer patients, a variety of clinical factors, including stages of the disease, ECOG/PS score, histological pathology, liver function and serum AFP (A fetal protein) levels, play a vital role.
patients with elevated AFP levels had a poorer prognosis than the general liver cancer population.
previous studies have shown that incremental changes in patient AFP levels (10- slt;100, 100-lt;1000, and ≥1000) at the time of HCC diagnosis were significantly associated with increased mortality, independent of several demographic factors, clinical factors, or treatment strategies.
the study aimed to assess the prognostic and predictive value of baseline AFP through post-analysis (post-hoc analyses) in two placebo-controlled trials (REACH, REACH-2), as well as the clinical outcomes of AFP responses or progressions.
OS and PFS phase researchers who responded to AFP by measuring serum AFP levels at baseline and every three cycles.
evaluated the prognostic and predictive value of baseline AFP through Cox regression models and sub-group efficacy pattern maps, and assessed the association between AFP (≥20% increase) and patients' imaging progression and efficacy.
results showed that baseline AFP levels were identified as a prognostic factor for continuous and di-distribution (≥400 vs .lt;400 ng/ml) trials, and were able to predict the survival benefits of patients treated with ramucirumab in the REACH trial.
percentage change in AFP showed an association between AFP and radioimaging progress at 6 weeks (risk ratio of 5.1) and 6-12 weeks (OR=1.8).
AFP response was higher in patients treated with reed monotherapy than in placebo.
further studies have shown that AFP patients have a longer lifetime than non-responding patients (13.6 months vs 5.6 months).
, the results show that AFP is an important prognostic factor and predictive biomarker for the survival benefits of reed monotherapy.
≥ 400 ng/ml afp is the appropriate selection criteria for Remo Reed monoantitons.